Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Astrazeneca Plc (AZN.LN)
Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 182,078,723
  • Shares Outstanding, K 1,549,870
  • Annual Sales, $ 44,351 M
  • Annual Income, $ 3,288 M
  • 60-Month Beta N/A
  • Price/Sales 5.23
  • Price/Cash Flow 23.64
  • Price/Book 6.37
Trade AZN.LN with:
  • Price/Earnings ttm 48.72
  • Earnings Per Share ttm 3.02
  • Most Recent Earnings 1.16 on 04/27/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield 3.26 (2.04%)
  • Most Recent Dividend 1.628 on 02/23/23
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
11,464.000 +2.48%
on 05/31/23
12,185.998 -3.59%
on 05/23/23
-26.002 (-0.22%)
since 05/02/23
3-Month
10,558.000 +11.27%
on 03/13/23
12,392.000 -5.20%
on 04/18/23
+884.000 (+8.14%)
since 03/02/23
52-Week
9,399.000 +24.99%
on 06/14/22
12,392.000 -5.20%
on 04/18/23
+1,306.000 (+12.51%)
since 06/01/22

Most Recent Stories

More News
Schrodinger is an AI-Powered Drug Discovery Developer to Watch

Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117

SDGR : 35.65 (+1.60%)
AZN.LN : 11,806.000 (+0.49%)
AZN : 72.59 (-0.34%)
AZNCF : 147.1200 (-0.39%)
LLY : 442.33 (+1.34%)
GSK : 34.11 (+0.92%)
GSK.LN : 1,381.300 (+1.00%)
ON : 86.83 (-1.27%)
PFE : 38.36 (+0.89%)
MRK : 112.52 (+1.43%)
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study ( NCT05257551 ), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers...

AZN : 72.59 (-0.34%)
AZN.LN : 11,806.000 (+0.49%)
Astrazeneca: Q3 Earnings Snapshot

Astrazeneca: Q3 Earnings Snapshot

AZN.LN : 11,806.000 (+0.49%)
AZN : 72.59 (-0.34%)
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis...

AZN : 72.59 (-0.34%)
AZN.LN : 11,806.000 (+0.49%)
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...

IPHA : 2.93 (+3.53%)
AZN.LN : 11,806.000 (+0.49%)
AZN : 72.59 (-0.34%)
Angeles Equity Partners Appoints Debbie White to Xanitos Board of Directors

Angeles Equity Partners, LLC (“Angeles”), a private investment firm focused on value creation through operational transformation, today announced the appointment of Debbie White to the Board of Directors...

IRV.LN : 6.048 (-36.97%)
HWDN.LN : 676.600 (+0.51%)
AZN.LN : 11,806.000 (+0.49%)
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in...

HCM : 12.50 (+3.05%)
HCM.LN : 200.000 (-0.35%)
AZN.LN : 11,806.000 (+0.49%)
AZN : 72.59 (-0.34%)
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and...

HCM : 12.50 (+3.05%)
HCM.LN : 200.000 (-0.35%)
AZN : 72.59 (-0.34%)
AZN.LN : 11,806.000 (+0.49%)
Global Industry Executive Debbie White Joins PAVmed Board of Directors

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company,...

PAVM : 0.4429 (+4.24%)
PAVMZ : 0.1200 (+20.00%)
HWDN.LN : 676.600 (+0.51%)
IRV.LN : 6.048 (-36.97%)
AZN.LN : 11,806.000 (+0.49%)
FibroGen Provides Regulatory Update on Roxadustat

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee...

AZN : 72.59 (-0.34%)
AZN.LN : 11,806.000 (+0.49%)
FGEN : 17.88 (+3.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 12,048.668
2nd Resistance Point 11,901.333
1st Resistance Point 11,824.667
Last Price 11,806.000
1st Support Level 11,600.666
2nd Support Level 11,453.331
3rd Support Level 11,376.665

See More

52-Week High 12,392.000
Last Price 11,806.000
Fibonacci 61.8% 11,248.674
Fibonacci 50% 10,895.500
Fibonacci 38.2% 10,542.326
52-Week Low 9,399.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar